Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Cyclic Peptide Platform as an Approach to Target Validation

Project description

Cyclic peptides chemical platform for validation of complex targets

The development of therapeutic agents requires novel methods for more efficient target validation for protein-protein and other complexes. Natural products like cyclic peptides represent a promising chemical platform for target validation. Recent technological advances have enabled the efficient production and screening of large libraries containing non-proteinogenic residues. The EU-funded CPTarget project aims to develop innovative chemical and molecular techniques to explore natural product-like cyclic peptides in target validation for complex, challenging targets. The goal is to enable the development of new therapeutic agents targeting multiple diseases, advancing methodology, and enabling new ways to investigate potential targets.

Objective

The current ‘genomics’ era is an exciting time for drug target discovery with considerable opportunities for therapeutic intervention. Whilst classical small molecules remain the reagents of choice as chemical probes for target validation, not all targets are tractable with small molecules. There is thus an urgent need to develop methods for more efficient target validation, not only of individual proteins but also of protein-protein and other complexes.
Natural product like cyclic peptides have enormous potential as a chemical platform for target validation. Recent technological advances have enabled the efficient production and screening of large libraries containing non-proteinogenic residues. De novo cyclic peptides with high affinity and selectivity for target proteins can be readily generated, even for protein-protein interaction targets perceived as challenging. Development of this technology and their innovative applications as outlined in our proposal will provide a step-change in methodology, and transform the current approach for studying the biological function of the target / pathways, enabling new ways to investigate potential targets.
We aim to develop innovative chemical and molecular techniques to explore the applications of natural product-like cyclic peptides in target validation for very challenging targets. Ultimately the work aims to enable the development of new therapeutic agents targeting multiple diseases.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

ERC-COG - Consolidator Grant

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2020-COG

See all projects funded under this call

Host institution

UNIVERSITY OF NEWCASTLE UPON TYNE
Net EU contribution
€ 2 241 271,00
Address
KINGS GATE
NE1 7RU Newcastle Upon Tyne
United Kingdom
Region
North East (England) Northumberland and Tyne and Wear Tyneside
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 2 241 271,00

Beneficiaries (1)